Literature DB >> 21936717

Drug resistance mutations in HIV pol sequences from Argentinean patients under antiretroviral treatment: subtype, gender, and age issues.

Leandro R Jones1, Franco Moretti, Andrea Y Calvo, Darío A Dilernia, Julieta M Manrique, Manuel Gómez-Carrillo, Horacio Salomón.   

Abstract

We studied drug resistance mutations (DRMs) in 2623 pol sequences. Out of 94,828 amino acid substitutions that were detected, 8749 corresponded to nucleoside reverse transcriptase inhibitor (NRTI), 3765 to nonnucleoside reverse transcriptase inhibitor (NNRTI), and 7141 to protease inhibitor (PI) resistance-associated mutations. The most common DRMs were L10I, I54V, L90M, V82A, A71V, L10V, M46I, M184V, M41L, T215Y, D67N, L210W, K70R, N348I, V118I, K103N, Y181C, G190A, K101E, V108I, L100I, V90I, K101Q, and A98G. As expected, DRMs frequencies depended on viral genotype. The amounts of NRTI and PI resistance mutations among B and BF sequences from children were higher than among sequences from adults. The frequencies of PI and NRTI resistance mutations among B and BF sequences from adult men were higher than among sequences from women. Some of these observations can be explained in light of the available epidemiological information, but some cannot, indicating that further studies are needed to understand the antiretroviral resistance epidemics in Argentina.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21936717      PMCID: PMC3399568          DOI: 10.1089/AID.2011.0287

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  24 in total

1.  Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection.

Authors:  Koyo Ariyoshi; Masakazu Matsuda; Hideka Miura; Sachiko Tateishi; Kaneo Yamada; Wataru Sugiura
Journal:  J Acquir Immune Defic Syndr       Date:  2003-07-01       Impact factor: 3.731

2.  HIV drug resistance.

Authors:  François Clavel; Allan J Hance
Journal:  N Engl J Med       Date:  2004-03-04       Impact factor: 91.245

3.  HIV type 1 genetic diversity surveillance among newly diagnosed individuals from 2003 to 2005 in Buenos Aires, Argentina.

Authors:  Dario A Dilernia; Alejandro M Gomez; Leonardo Lourtau; Rubén Marone; Marcelo H Losso; Horacio Salomón; Manuel Gómez-Carrillo
Journal:  AIDS Res Hum Retroviruses       Date:  2007-10       Impact factor: 2.205

4.  Sex-based differences in T lymphocyte responses in HIV-1-seropositive individuals.

Authors:  Timothy R Sterling; Tracy Pisell-Noland; John L Perez; Jacquie Astemborski; Joelle R McGriff; Lisa Nutting; Donald R Hoover; David Vlahov; Robert C Bollinger
Journal:  J Infect Dis       Date:  2005-02-07       Impact factor: 5.226

5.  Genotypic predictors of human immunodeficiency virus type 1 drug resistance.

Authors:  Soo-Yon Rhee; Jonathan Taylor; Gauhar Wadhera; Asa Ben-Hur; Douglas L Brutlag; Robert W Shafer
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-25       Impact factor: 11.205

Review 6.  Epidemiology of antiretroviral drug resistance in drug-naïve persons.

Authors:  Anna Maria Geretti
Journal:  Curr Opin Infect Dis       Date:  2007-02       Impact factor: 4.915

7.  Identification of breakpoints in intergenotypic recombinants of HIV type 1 by bootscanning.

Authors:  M O Salminen; J K Carr; D S Burke; F E McCutchan
Journal:  AIDS Res Hum Retroviruses       Date:  1995-11       Impact factor: 2.205

8.  Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters.

Authors:  T R Sterling; C M Lyles; D Vlahov; J Astemborski; J B Margolick; T C Quinn
Journal:  J Infect Dis       Date:  1999-09       Impact factor: 5.226

9.  Sex differences in HIV-1 viral load and progression to AIDS.

Authors:  H Farzadegan; D R Hoover; J Astemborski; C M Lyles; J B Margolick; R B Markham; T C Quinn; D Vlahov
Journal:  Lancet       Date:  1998-11-07       Impact factor: 79.321

10.  Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration.

Authors:  Rami Kantor; David A Katzenstein; Brad Efron; Ana Patricia Carvalho; Brian Wynhoven; Patricia Cane; John Clarke; Sunee Sirivichayakul; Marcelo A Soares; Joke Snoeck; Candice Pillay; Hagit Rudich; Rosangela Rodrigues; Africa Holguin; Koya Ariyoshi; Maria Belen Bouzas; Pedro Cahn; Wataru Sugiura; Vincent Soriano; Luis F Brigido; Zehava Grossman; Lynn Morris; Anne-Mieke Vandamme; Amilcar Tanuri; Praphan Phanuphak; Jonathan N Weber; Deenan Pillay; P Richard Harrigan; Ricardo Camacho; Jonathan M Schapiro; Robert W Shafer
Journal:  PLoS Med       Date:  2005-04-26       Impact factor: 11.069

View more
  2 in total

1.  Trends in prevalence of HIV-1 drug resistance in Thailand 2009-2010.

Authors:  Sayompoo Sanguansittianant; Nattakarn Nooroon; Poonlaph Phaengchomduan; Palanee Ammaranond
Journal:  J Clin Lab Anal       Date:  2013-09       Impact factor: 2.352

2.  A cross-sectional study to evaluate second line virological failure and elevated bilirubin as a surrogate for adherence to atazanavir/ritonavir in two urban HIV clinics in Lilongwe, Malawi.

Authors:  Dennis Miyoge Ongubo; Robertino Lim; Hannock Tweya; Christopher Chikhosi Stanley; Petros Tembo; Richard Broadhurst; Salem Gugsa; McNeil Ngongondo; Colin Speight; Tom Heller; Sam Phiri; Mina C Hosseinipour
Journal:  BMC Infect Dis       Date:  2017-07-03       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.